FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma
FCGR2B knockdown in tumor-associated macrophages enhances their anti-tumor capabilities by reducing M2 polarization and improving phagocytosis.
Asset / Drug
Drug and asset intelligence for FCGR2B with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.